Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sivelestat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE known ✓ | P08246 | 16/20 | 0.71 |
| ▸ | PRTN3 | P24158 | 12/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sivelestat SCHEMBL123221 | 1.00 | ELANE (0.71) | ELANEPRTN3NPC1RAB9AKDM4E | |
| Sivelestat SCHEMBL28751433 | 1.00 | ELANE (0.71) | ELANEPRTN3NPC1RAB9AKDM4E | |
| Sivelestat SCHEMBL566914 | 0.99 | ELANE (0.69) | ELANEPRTN3NPC1RAB9AKDM4E | |
| Sivelestat SCHEMBL6690886 | 0.99 | ELANE (0.69) | ELANEPRTN3NPC1RAB9AKDM4E | |
| Sivelestat SCHEMBL30864380 | 0.99 | ELANE (0.69) | ELANEPRTN3NPC1RAB9AKDM4E | |
| Sivelestat SCHEMBL1499929 | 0.98 | ELANE (0.68) | ELANEPRTN3NPC1RAB9AKDM4E | |
| Sivelestat SCHEMBL597819 | 0.98 | ELANE (0.68) | ELANEPRTN3NPC1RAB9AKDM4E | |
| SCHEMBL7267891 | 0.92 | ELANE (0.71) | ELANEPRTN3KDM4EGAAHSD17B10 | |
| SCHEMBL9777074 | 0.91 | ELANE (0.69) | ELANEPRTN3NPC1KDM4EGAA | |
| Sivelestat SCHEMBL4411778 | 0.91 | ELANE (0.69) | ELANEPRTN3NPC1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638556-B2 | Freeze-dried product of N-[o-(p-pivaloyloxy benzenesulfonylamino)benzoyl]glycine monosodium salt tetra-hydrate and a process for the manufacture thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-29 | — | — | US | claimed |
| US-20070203357-A1 | FREEZE-DRIED PRODUCT OF N-[O-(P-PIVALOYLOXY BENZENESULFONYLAMINO) BENZOYL]GLYCINE MONOSODIUM SALT TETRA-HYDRATE AND A PROCESS FOR THE MANUFACTURE THEREOF | ONO PHARMACEUTICAL CO., LTD. | 2007-08-30 | — | — | US | claimed |
| EP-1393727-B1 | REMEDIAL AGENT FOR MYELOPATHIC DISEASE | ONO PHARMACEUTICAL CO (JP) | 2007-04-18 | — | — | EP | claimed |
| US-20050101633-A1 | Remedial agent for myelopathic disease | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | claimed |
| US-20040092587-A1 | Freeze-dried preparation of n[o-(p-pivaloyloxybenzenesulfonylamino) benzoyl] glycine monosodium salt tetrahydrate and process for producing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | US | claimed |
| EP-1393727-A1 | REMEDIAL AGENT FOR MYELOPATHIC DISEASE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-03-03 | — | — | EP | claimed |
| EP-1166773-B1 | Solution of N- O(p-pivaloyloxbenzenesulfonylamino)benzoyl glycine monosodium salt tetra-hydrate and drug product thereof | ONO PHARMACEUTICAL CO (JP) | 2004-02-11 | — | — | EP | claimed |
| US-6624193-B1 | Prophylactic and therapeutic medicament for ophthalmic diseases, especially ophthalmic inflammatory diseases and corneal ulcer, comprising as an active ingredient a compound represented by the formula phenylcarboxylate amidesulfonamide | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-09-23 | — | — | US | claimed |
| EP-1304106-A1 | FREEZE-DRIED PREPARATION OF N- o-(p-PIVALOYLOXYBENZENESULFONYLAMINO)BENZOYL]GLYCINE MONOSODIUM SALT TETRAHYDRATE AND PROCESS FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-04-23 | — | — | EP | claimed |
| US-6552082-B2 | Solubility makes it possible to manufacture a solution of higher concentration of the compound and high-dosage drug product | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-04-22 | — | — | US | claimed |
| EP-1213018-A1 | PREVENTIVE AND THERAPEUTIC AGENTS FOR EYE DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-12 | — | — | EP | claimed |
| US-20020022738-A1 | Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-02-21 | — | — | US | claimed |
| EP-1166773-A1 | Solution of N- O(p-pivaloyloxbenzenesulfonylamino)benzoyl glycine monosodium salt tetra-hydrate and drug product thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-01-02 | — | — | EP | claimed |
| JP-9040692-A | — | — | None | — | — | JP | disclosed |
| CN-118161458-A | Freeze-dried preparation of ciliristat sodium and preparation method thereof | 牡丹江市第二人民医院 | 2024-06-11 | — | — | CN | disclosed |
| US-7638556-B2 | Freeze-dried product of N-[o-(p-pivaloyloxy benzenesulfonylamino)benzoyl]glycine monosodium salt tetra-hydrate and a process for the manufacture thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-29 | — | — | US | disclosed |
| US-5359121-A | N-(o-(p-pivaloyloxybenzenesulfonylamino)benzoyl)glycine benzyl ester; elastase inhibitor; useful for treatment of emphysema, atherosclerosis, rheumatoid arthritis | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-10-25 | — | — | US | disclosed |
| US-5359121-A | N-(o-(p-pivaloyloxybenzenesulfonylamino)benzoyl)glycine benzyl ester; elastase inhibitor; useful for treatment of emphysema, atherosclerosis, rheumatoid arthritis | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-10-25 | — | — | US | disclosed |
| EP-0539223-A1 | Glycine derivative monosodium salt tetrahydrate having an inhibitory effect on elastase | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-04-28 | — | — | EP | disclosed |
| EP-0539223-A1 | Glycine derivative monosodium salt tetrahydrate having an inhibitory effect on elastase | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203357-A1 | FREEZE-DRIED PRODUCT OF N-[O-(P-PIVALOYLOXY BENZENESULFONYLAMINO) BENZOYL]GLYCINE MONOSODIUM SALT TETRA-HYDRATE AND A PROCESS FOR THE MANUFACTURE THEREOF | SLC6A5, SLC6A9, SLC6A6 | ELANE 3536/4885PRTN3 3806/4885NPC1 2618/4885 |
| US-20020022738-A1 | Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof | SLC6A5, ABCB11, SLC6A1 | ELANE 4496/4885PRTN3 3836/4885NPC1 2119/4885 |
| US-20040092587-A1 | Freeze-dried preparation of n[o-(p-pivaloyloxybenzenesulfonylamino) benzoyl] glycine monosodium salt tetrahydrate and process for producing the same | SLC6A5, SI, PFAS | ELANE 3459/4885PRTN3 3551/4885NPC1 2963/4885 |
| US-20050101633-A1 | Remedial agent for myelopathic disease | NR1H2, MSR1, NR1H3 | ELANE 2565/4885PRTN3 382/4885NPC1 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.